BiotechTube

PLX3397

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Trial Timeline

Mar 3, 2011 → Apr 26, 2012

NCT ID
NCT01217229

About PLX3397

PLX3397 is a phase 2 stage product being developed by Daiichi Sankyo for Hodgkin Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01217229. Target conditions include Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (5)

NCT IDPhaseStatus
NCT02975700Pre-clinicalCompleted
NCT01499043Phase 2Terminated
NCT01349036Phase 2Terminated
NCT01217229Phase 2Completed
NCT01004861Phase 1Completed

Competing Products

20 competing products in Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM13AffimedPhase 2
44
VIP152 + BTKiVincerx PharmaPhase 1
25
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
TirabrutinibOno PharmaceuticalPhase 1
33
ONO-7018Ono PharmaceuticalPhase 1
33
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
77
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
R-mabHDI and ABVD + ABVDEli LillyPhase 3
77
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
41
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
R-mabHD + ABVDEli LillyPhase 2
52
enzastaurin + placeboEli LillyPhase 3
77
LY317615Eli LillyPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85